Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) EBT Margin (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EBT Margin for 16 consecutive years, with 0.57% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin fell 1403.0% to 0.57% in Q4 2025 year-over-year; TTM through Dec 2025 was 9.08%, a 1163.0% decrease, with the full-year FY2025 number at 9.08%, down 1018.0% from a year prior.
  • EBT Margin was 0.57% for Q4 2025 at Anika Therapeutics, up from 8.04% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 23.93% in Q2 2021 to a low of 846.64% in Q4 2023.
  • A 5-year average of 70.57% and a median of 8.16% in 2025 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: tumbled -42969bps in 2022, then soared 86009bps in 2024.
  • Anika Therapeutics' EBT Margin stood at 25.6% in 2021, then crashed by -1679bps to 455.29% in 2022, then crashed by -86bps to 846.64% in 2023, then soared by 102bps to 13.45% in 2024, then tumbled by -104bps to 0.57% in 2025.
  • Per Business Quant, the three most recent readings for ANIK's EBT Margin are 0.57% (Q4 2025), 8.04% (Q3 2025), and 14.05% (Q2 2025).